{
    "clinical_study": {
        "@rank": "115",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04343248"
        },
        "id_info": {
            "org_study_id": "RM08-3006",
            "nct_id": "NCT04343248"
        },
        "brief_title": "A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)",
        "official_title": "A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Romark Laboratories L.C.",
                "agency_class": "Industry"
            }
        },
        "source": "Romark Laboratories L.C.",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "Yes",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19\n      and other VRIs in elderly LTCF residents."
        },
        "detailed_description": {
            "textblock": "Multicenter, randomized, double-blind, placebo-controlled, trial to evaluate the efficacy and\n      safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF\n      residents."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 30, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "August 31, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "August 31, 2020"
        },
        "phase": "Phase 3",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Prevention",
            "masking": "Triple (Participant, Care Provider, Investigator)"
        },
        "primary_outcome": [
            {
                "measure": "Symptomatic laboratory-confirmed COVID-19",
                "time_frame": "up to 6 weeks",
                "description": "The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period."
            },
            {
                "measure": "Symptomatic laboratory-confirmed VRI",
                "time_frame": "up to 6 weeks",
                "description": "The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period."
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "300"
        },
        "condition": [
            "COVID-19",
            "Viral Respiratory Illnesses"
        ],
        "arm_group": [
            {
                "arm_group_label": "Nitazoxanide",
                "arm_group_type": "Active Comparator",
                "description": "Two Nitazoxanide 300 mg tablets orally twice daily for 6 weeks"
            },
            {
                "arm_group_label": "Placebo",
                "arm_group_type": "Placebo Comparator",
                "description": "Two placebo tablets orally twice daily for 6 weeks"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Nitazoxanide",
                "description": "Nitazoxanide 600 mg administered orally twice daily for six weeks",
                "arm_group_label": "Nitazoxanide",
                "other_name": [
                    "NTZ (nitazoxanide)",
                    "NT-300"
                ]
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Placebo",
                "description": "Placebo administered orally twice daily for six weeks",
                "arm_group_label": "Placebo"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female residents of LTCFs at least 65 years of age.\n\n          -  Willing and able to provide written informed consent and comply with the requirements\n             of the protocol.\n\n          -  At least one symptomatic laboratory-confirmed viral respiratory infection identified\n             in the LTCF within 7 days prior to enrollment.\n\n        Exclusion Criteria:\n\n          -  Alzheimer's disease, dementia, or other mental incapacity which precludes\n             comprehension of the study requirements or symptom diary.\n\n          -  Subjects expected to require hospitalization within the 6-week treatment period.\n\n          -  Subjects who experienced a previous episode of acute upper respiratory tract\n             infection, otitis, bronchitis or sinusitis or received antibiotics for these\n             conditions or antiviral therapy for influenza within two weeks prior to and including\n             study day 1.\n\n          -  Receipt of any dose of NTZ within 7 days prior to screening.\n\n          -  Treatment with any investigational drug or vaccine within 30 days prior to screening\n             or unwilling to avoid them during the course of the study.\n\n          -  Known sensitivity to NTZ or any of the excipients comprising the study medication.\n\n          -  Subjects unable to swallow oral tablets or capsules.\n\n          -  Subjects taking medications considered to be major CYP2C8 substrates.\n\n          -  Subjects who, in the judgment of the Investigator, will be unlikely to comply with the\n             requirements of this protocol."
            },
            "gender": "All",
            "minimum_age": "65 Years",
            "maximum_age": "120 Years",
            "healthy_volunteers": "No"
        },
        "overall_contact": {
            "last_name": "Matthew Bardin, PharmD, BCPS",
            "phone": "813-282-8544",
            "email": "matthew.bardin@romark.com"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 8, 2020",
        "study_first_submitted_qc": "April 8, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 13, 2020"
        },
        "last_update_submitted": "April 8, 2020",
        "last_update_submitted_qc": "April 8, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 13, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": [
            "COVID-19",
            "Viral Respiratory Illnesses"
        ],
        "intervention_browse": {
            "mesh_term": "Nitazoxanide"
        }
    }
}